Common Contracts
3 similar Clinical Study Agreement contracts
Clinical Study Agreement Protocol: DAL-301 Site: 18-105 XXXXX DalCor Pharma UK Ltd 12-MAY-2016 Version: 1.0 Country : Czech republic Smlouva o klinické studii Protokol: DAL-301 Centrum: 18-105 XXXXX DalCor Pharma UK Ltd 12-KVĚTEN-2016 Verze: 1.0 Země:...Clinical Study Agreement • October 19th, 2017
CLINICAL STUDY AGREEMENT This clinical study agreement (“Agreement”), effective as of 12-MAY-2016 (the “Effective Date”), is entered into by and between Medpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA (“Medpace”), represented by XXXXX; Krajska nemocnice T.Bati, a. s., a clinical research site with its principal office and place of business at Havlickovo nabrezi 600, 762 75 Zlin, Czech Republic (“Institution”), represented by XXXXX, chairman of the board and XXXXX, Institution registered in the Commercial Register at the Regional Court in Brno, section B, Insertion 4437; and XXXXX, with his principal office and place of business at Krajska nemocnice T.Bati, a. s., Havlickovo nabrezi 600, 762 75 Zlin, Czech Republic (“Principal Investigator”). Medpace, Institution, and Principal Investigator are sometimes collectively referred to herein as parties (the “Parties”). WHEREAS, DalCor Pharma UK Ltd (“Sponsor”) is sponsoring a cli
CLINICAL STUDY AGREEMENT PROTOCOL: DAL-301 SITE: 18-103I DALCOR PHARMA UK LTD 10- MAY- 2016 VERSION: 1 . 0 COUNTRY : CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL: DAL-301 CENTRUM: 18 -103 DALCOR PHARMA UK LTD 10- KVĚTEN- 2016 VERZE: 1 . 0 ZEMĚ:...Clinical Study Agreement • November 7th, 2016
CLINICAL STUDY SMLOUVA O KLINICKÉ AGREEMENT STUDII This clinical study agreement (“Agreement”), effective as of the day last signature under the Agreement (the “Effective Date”), is entered into by and between Medpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA (“Medpace”), identification number in the USA: 1309161, represented by; whose valid authorization for representation with an apostille form is an integral part to this agreement, and Oblastni nemocnice Kladno, a.s., nemocnice Stredoceskeho kraje, with its principal office and place of business at Vančurova 1548, 272 59 Kladno, Czech Republic (“Institution”), ID no.: 27256537, registered in the Companies Register managed by the Municipal Court in Prague under ref. no. 10020, represented by,with his principal office and place of business at Oblastni nemocnice Kladno, a.s., nemocnice Stredoceskeho kraje, Vančurova 1548, 272 59 Kladno, Czech Republic (“Principal Investigato
CLINICAL STUDY AGREEMENT PROTOCOL: DAL-301 SITE: 18-106 DALCOR PHARMA UK LTD 07 - OCT- 2016 VERSION: 1 . 0 COUNTRY : CZECH REPUBLIC SMLOUVA O KLINICKÉ STUDII PROTOKOL: DAL-301 CENTRUM: 18-106 DALCOR PHARMA UK LTD 07 - ŘÍJEN- 2016 VERZE: 1 . 0 ZEMĚ:...Clinical Study Agreement • October 11th, 2016
CLINICAL STUDY AGREEMENTThis clinical study agreement (“Agreement”), dated 07-OCT-2016 (the “Effective Date”), is entered into by and between the partiesMedpace, Inc., with its principal office and place of business at 5375 Medpace Way, Cincinnati, Ohio 45227, USA (“Medpace”),andFakultni nemocnice Brno, a clinical research site with its principal office and place of business at Jihlavska 20, 625 00 Brno, Czech Republic, company registration number: 65269705, tax identification number: CZ65269705 (“Institution”),and .Medpace, Institution, and Principal Investigator are sometimes collectively referred to herein as parties (the “Parties”). DalCor Pharma UK Ltd (“Sponsor”) is sponsoring a clinical study on the compound Dalcetrapib (the “Study Drug”), in accordance with Protocol No. DAL-301, titled “A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary
